
Opinion|Videos|November 25, 2024
Current Landscape of Bispecific Therapies for RRMM
Key Takeaways
- Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
- Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following
- Provide a brief overview of the bispecific therapies currently available for the treatment of relapsed/refractory multiple myeloma (RRMM).
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Toothpaste Tablets Are Gaining Popularity—Here’s Where Pharmacists Fit In
2
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
3
Federal Health Officials Scale Back Number of Recommended Vaccines for Children
4
Federal Cervical Cancer Testing Guidelines Expanded to Allow Self-Administered HPV Test
5












































































































































































































